Note they don't disclose the 6 week/6 week gain this time. First time they've done that. I think that's because the Rx #'s are down. Naturally orph is up a bit :-)
Press Release Source: Orphan Medical, Inc.
Orphan Medical Issues Xyrem Prescriptions and sNDA Update
Monday November 29, 2:48 pm ET
Company Reaffirms Total 2004 Revenue Guidance of $23 to $24 million
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 29, 2004--ORPHAN MEDICAL, INC. (Nasdaq:ORPH - News) announced that the total number of Xyrem® (sodium oxybate) oral solution prescriptions filled in the six-week period ended November 15, 2004 was 4,374. The Company reaffirmed its 2004 guidance of $23 to $24 million in total revenue including $10.5 to $11.0 million in revenue from Xyrem, the first and only approved treatment for cataplexy associated with narcolepsy. The Company also announced that its supplemental New Drug Application (sNDA) filing to expand the Xyrem label to encompass improvement in the other primary symptoms of narcolepsy is expected to be submitted to the Food and Drug Administration in late December or January.
Market Data 
Markets 
AI
